Capital Fund Management S.A. Boosts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Capital Fund Management S.A. increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 13.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,786 shares of the medical research company’s stock after acquiring an additional 3,371 shares during the quarter. Capital Fund Management S.A.’s holdings in Charles River Laboratories International were worth $5,129,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. F M Investments LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $361,000. CenterBook Partners LP acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $4,729,000. Raymond James Financial Inc. purchased a new position in Charles River Laboratories International during the fourth quarter worth approximately $42,776,000. APG Asset Management N.V. boosted its stake in Charles River Laboratories International by 288.2% during the fourth quarter. APG Asset Management N.V. now owns 30,104 shares of the medical research company’s stock worth $5,367,000 after buying an additional 22,349 shares during the last quarter. Finally, Bank of Nova Scotia grew its holdings in Charles River Laboratories International by 4.9% in the 4th quarter. Bank of Nova Scotia now owns 5,011 shares of the medical research company’s stock valued at $925,000 after buying an additional 232 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on CRL shares. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. Barclays reduced their target price on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Thursday. Robert W. Baird dropped their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, Mizuho lowered their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus target price of $182.00.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Price Performance

CRL opened at $99.56 on Monday. The stock’s 50-day moving average price is $156.71 and its 200 day moving average price is $176.86. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The firm has a market cap of $4.89 billion, a price-to-earnings ratio of 663.71, a PEG ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.46 earnings per share. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).